Who is sponsoring NCT02342145?

NCT02342145 is sponsored by Zhongming Zhang.

What condition does NCT02342145 study?

NCT02342145 studies Beta-Thalassemia Major, Graft-versus-host Disease (GVHD).

What drugs are being tested in NCT02342145?

Interventions: Basiliximab,, Tacrolimus, Methotrexate, Mycophenolate mofetil.

What is the status of NCT02342145?

NCT02342145 is currently COMPLETED.

Last reviewed 2025-06-15 · How we verify

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study

NCT02342145 Phase 4 COMPLETED

The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major. The objective was to evaluate the effect and safety of basiliximab for acute graft-versus-host disease.

Details

Lead sponsor	Zhongming Zhang
Phase	Phase 4
Status	COMPLETED
Enrolment	205
Start date	2015-04
Completion	2022-08-20

Conditions

Beta-Thalassemia Major
Graft-versus-host Disease (GVHD)

Interventions

Basiliximab,
Tacrolimus
Methotrexate
Mycophenolate mofetil

Primary outcomes

grade II-IV acute graft-versus-host disease incidence — 100 days after matched unrelated donor hematopoietic stem cell transplantation.
The cumulative incidence of grade II-IV acute graft-versus-host disease after matched unrelated donor hematopoietic stem cell transplantation +100d.

Countries

China